Market Access

Kevin Dondarski from Deloitte Consulting discusses how changes in industry trends are causing pharma companies to explore new market opportunities provided by the rise of GLP-1 medications.

Mike Petroutsas, president and head of U.S. commercial at Astellas, explores the importance of insight-driven commercialization in reshaping how manufacturers engage patients, physicians and the broader healthcare ecosystem.

At the Doceree Makers Summit, leaders from Sanofi, Bristol Myers Squibb, Eli Lilly, and others backed a new pharma marketing operating model to replace fragmented legacy softwares.

How existing technologies and approaches such as targeted AI deployment can help make prior authorization workflows more efficient.

Agentic AI is reshaping pharma market entry by enabling real-time, data-driven insights that allow companies to ask more complex strategic questions and act faster — with greater precision.

An expected surge in generic GLP-1s is anticipated to reshape not only pharmaceutical pricing and access but also the global MedTech ecosystem supporting drug delivery.

Natalie de Graaf, from the API Innovation Center, discusses a recent whitepaper detailing areas where the generic drugs pipeline is under stress.

Charlie Lyon, VP of manufacturing, procurement, and logistics at the API Innovation Center, discusses the complicated web of global manufacturing.

Why biopharma's targeting model is overdue for evolution.

Aradigm CEO Will Shrank discusses the significant challenge payers face in predicting and managing the costs of cell and gene therapies due to their volatility and unpredictability.

MaxCyte’s CEO explains the various ways CGT is impacted by new technologies and methods of treatment delivery.

Model N’s Michael Grosberg breaks down the accelerated complexity, policy disruption, and data gaps testing manufacturer market access and revenue management strategies.

Market analysts are comparing Foundayo’s sales with other GLP-1 medications, such as the oral version of Wegovy.

Morten Graugaard, CEO, Orbis Medicines, discusses the importance of oral biologics and the industry impacts of FDA's approval of Icotyde.

Novo Nordisk’s U.S. launch of a higher-dose Wegovy formulation highlights Novo's effort to extend efficacy, capture broader patient demand, and reinforce its dominance in the rapidly expanding obesity market.

Where PBMs fit into the new market access landscape, how pharma companies can respond and the questions that remain.

Analysis of U.S. drug pricing reform in 2026 highlights how the Inflation Reduction Act, Medicare drug price negotiation, and most-favored-nation pricing initiatives are reshaping pharmaceutical pricing, limiting patent-driven market exclusivity, accelerating generic and biosimilar competition, and driving strategic shifts in market access, pricing models, and innovation priorities across the biopharma industry.

Shionogi completed its $2.5 billion acquisition of global rights to Radicava from Tanabe Pharma, adding one of the few approved treatments for ALS to its portfolio .

Regulators are shifting antitrust scrutiny in healthcare from market share and pricing toward how vertically integrated systems shape patient flow, access, and competitive dynamics, signaling deeper oversight of ecosystem design, strategic intent, and cumulative market influence.

Novo Nordisk launched a multi-month Wegovy subscription program offering fixed monthly pricing through telehealth providers, aiming to improve affordability and long-term adherence among self-pay patients.

For pharma products, ensuring proper delivery requires the majority of work to occur before the product hits the road.

eHealth’s vice president of consumer enablement discusses pricing and cost issues with GLP-1s.

CMS’s 2026 requirement for manufacturers to submit “reasonable assumptions” alongside ASP data formalizes the role of estimation in drug pricing, increasing scrutiny on how ASP is constructed and shifting reporting toward greater transparency and accountability.

Pharma products face unique issues related to chain-of-custody and cold chain.

A comparison of TrumpRx.gov prices against UK National Health Service pharmacy payouts found that drugs from several major manufacturers remain significantly cheaper under the British system.